Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (9029)	11/21/2005 3:42:49 PM
From: Biomaven	Read Replies (2) \| Respond to of 10280

The trouble is that the trial would have to be very large because the event rate is so low. The FDA warning was based on a 26k patient trial lasting 28 weeks. The long-acting drug salmeterol had 13 deaths vs. 3 deaths with placebo (both given on top of usual therapy). Further, you couldn't blind the trial because arformoterol is only available as a neb. May not matter if you take death as the endpoint, but would be a problem for efficacy endpoints. Peter